Guangzhou Baiyunshan Pharmaceutical Holdings Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Hong Li
Chief executive officer
CN¥1.5m
Total compensation
| CEO salary percentage | 30.6% |
| CEO tenure | 7.5yrs |
| CEO ownership | n/a |
| Management average tenure | 7.5yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥3b |
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥2m | CN¥471k | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥460k | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥2m | CN¥456k | CN¥4b |
| Sep 30 2021 | n/a | n/a | CN¥4b |
| Jun 30 2021 | n/a | n/a | CN¥4b |
| Mar 31 2021 | n/a | n/a | CN¥3b |
| Dec 31 2020 | CN¥1m | CN¥442k | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥3b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥1m | CN¥428k | CN¥3b |
| Sep 30 2019 | n/a | n/a | CN¥3b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥4b |
| Dec 31 2018 | CN¥1m | CN¥382k | CN¥3b |
Compensation vs Market: Hong's total compensation ($USD210.94K) is below average for companies of similar size in the Hong Kong market ($USD788.79K).
Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.
CEO
Hong Li (57 yo)
7.5yrs
Tenure
CN¥1,539,030
Compensation
Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 7.5yrs | CN¥1.54m | no data | |
| Executive Vice Chairman | 12.3yrs | no data | no data | |
| Executive Vice Chairman | 4.9yrs | no data | no data | |
| Deputy GM & Executive Director | 9.9yrs | CN¥1.57m | no data | |
| Executive Director | no data | no data | no data | |
| Deputy GM & Director of Business Administration Department | 5.4yrs | CN¥1.41m | no data | |
| Secretary | 7.7yrs | CN¥1.24m | no data |
7.5yrs
Average Tenure
57yo
Average Age
Experienced Management: 874's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 6.5yrs | CN¥1.54m | no data | |
| Executive Vice Chairman | 12.3yrs | no data | no data | |
| Executive Vice Chairman | 4.9yrs | no data | no data | |
| Deputy GM & Executive Director | 14.5yrs | CN¥1.57m | no data | |
| Executive Director | 10.9yrs | no data | no data | |
| Independent Non-Executive Director | 1.6yrs | CN¥50.00k | no data | |
| Chairman of the Supervisory Board | 5.3yrs | no data | no data | |
| Supervisor | 4.9yrs | no data | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥120.00k | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥120.00k | no data | |
| Supervisor | 3.5yrs | no data | no data | |
| Independent Non-Executive Director | 1.6yrs | CN¥70.00k | no data |
4.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 874's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is covered by 29 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| null null | BOCI Research Ltd. |
| Feng Qiang Sun | BOCOM International Securities Limited |